Precision BioSciences, Inc. (DTIL)

Several events have impacted Precision BioSciences' stock price in the past six months. In September 2025, the company presented clinical data from its Phase 1 ELIMINATE-B trial of PBGENE-HBV, showing the therapy was well-tolerated and active. In November 2025, Precision BioSciences reported its third-quarter 2025 financial results, missing analyst expectations, and announced a $75 million underwritten offering of common stock. In March 2026, Precision BioSciences received $7.5 million in proceeds from TG Therapeutics for an Azer-cel clinical milestone. The FDA granted Fast Track designation to PBGENE-DMD, leading to a rise in shares. Precision BioSciences presented new preclinical data for PBGENE-DMD at the Muscular Dystrophy Association Clinical & Scientific Conference 2026. The company received two Notices of Allowance from the U.S. Patent and Trademark Office for patent applications covering its PBGENE-HBV program. Precision BioSciences reported its fourth-quarter and fiscal year 2025 financial results, surpassing expectations. Jones Trading reiterated a Buy rating and a $30.00 price target on DTIL following the announcement of its Phase 1/2 trial design for PBGENE-DMD.

Precision BioSciences exhibits some demand seasonality in its stock performance based on historical data. November has been the strongest month for DTIL stock, while December has tended to be the weakest month. The overall monthly win rate for the stock is 38.8%, with three months typically showing positive average returns. Traditional product or service demand seasonality is not directly applicable to its gene editing therapies.

Precision BioSciences is a clinical-stage biotechnology company focused on developing in vivo gene editing therapies using its ARCUS® genome editing platform. The company's core business revolves around its ARCUS® platform, designed for therapeutic safety, delivery, and control, enabling precise DNA insertion, excision, and elimination. The company's pipeline includes PBGENE-HBV for chronic Hepatitis B virus, PBGENE-DMD for Duchenne muscular dystrophy, PBGENE-3243 for m.3243 associated primary mitochondrial myopathy, and iECURE-OTC for ornithine transcarbamylase deficiency. The company also has other preclinical programs targeting liver, CNS, and mitochondrial diseases.

Precision BioSciences is headquartered in Durham, North Carolina, United States. The company conducts global clinical activities, with approved Investigational New Drug (IND) applications and Clinical Trial Authorizations (CTAs) in the US, UK, and Australia for its lead programs.

Precision BioSciences' brand reputation appears to be characterized by cautious optimism and excitement around its clinical pipeline. The company has received a consensus "Hold" rating from analysts, with some "Buy" ratings. Positive events include promising early clinical data for PBGENE-HBV and preclinical advancements for PBGENE-DMD. The FDA's Fast Track designation for PBGENE-DMD also positively impacted its standing. However, the company has faced financial challenges, including revenue misses and ongoing net losses in previous quarters, and shareholder dilution from equity financing has also been noted.

Precision BioSciences, Inc. has a significant institutional ownership, with 61.57% of its shares held by institutions. Individual investors hold 4.36% of the shares.